Searched for
NIRMATRELVIR
Over 20% Covid-infected people taking Paxlovid experience viral rebound: StudyA study by researchers at Mass General Brigham hospital in Boston found that one in five COVID-infected individuals treated with antiviral ...- Hetero's oral drug gets WHO PrequalificationIt is the first prequalification for a generic version of Pfizer's Covid-19 oral antiviral drug paxlovid, the company said. The WHO made a ...
- Hetero gets WHO prequalification for generic Covid antiviral PaxlovidThis is the first WHO prequalification for Paxlovid - a combination of nirmatrelvir and ritonavir which is recommended for treating mild an...
- Why do some people who take Paxlovid for Covid get 'rebound' symptoms or test positive again?In a clinical trial, Paxlovid showed an 89% reduction in the risk of hospitalisation and death.
- Zenara Gets Nod to Manufacture, Sell Pfizer's PaxlovidThe company said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatmen...
- Zenara Pharma gets CDSCO nod to launch Covid antiviral Paxlovid in IndiaThe approval by the Central Drugs Standard Control Organization (CDSCO) has been granted under the emergency authorization route considerin...
- Zenara pharma to launch generic Paxlovid soonThe company said that Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms ...
- ICMR task force meets to discuss inclusion of Pfizer’s Paxlovid for Covid treatmentPfizer’s Paxlovid contains Nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and Ritonavir, which slows...
- Pfizer's "game-changing" COVID-19 pill, Paxlovid, gets DCGI nodPfizer had last year announced a deal with MPP, a UN-backed body, to issue royalty-free voluntary licences to manufacture generic versions ...
- World Health Organization 'strongly recommends' Pfizer's COVID-19 pillUS pharma giant Pfizer's combination of nirmatrelvir and ritonavir was the "superior choice" of treatment for unvaccinated, elderly or immu...
- Stocks in the news: RIL, Granules India, HDFC, SBI, Dodla Dairy and NMDCReliance Retail Ventures announced the acquisition of a majority 89 per cent equity stake in Clovia, an industry leader in the bridge-to-pr...
- 19 Indian companies get licence to make Pfizer's oral genericThese include Cipla, Sun Pharma, Laurus Labs, Divi's Laboratories, Glenmark, Emcure, Macleods, SMS Pharmaceuticals, Strides, Torrent, Cadil...
- Torrent & Cadila Pharmaceuticals get license to manufacture oral antiviral Covid-19 pill nirmatrelvirTorrent said that t it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how ...
- Torrent & Aurobindo receive licenses to sell Pfizer's COVID pill Paxlovid in India, low income countriesThe oral COVID-19 treatment comprises of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating and ritonavir...
- Pfizer may offer Covid antiviral drug to India at lower price for nowPfizer has entered into advance purchase agreements with multiple countries. Sources told ET that Pfizer is yet to apply for emergency use ...
- Bangladeshi firm launches first generic of Pfizer drugBangladesh's directorate general of drug administration on Thursday granted emergency use authorisation for the oral antiviral drug to trea...
- Bangladesh drug maker Beximco launches world's first generic of Pfizer's COVID antiviralPfizer's novel antiviral pill showed almost 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent data f...
- US nod in Hand, Pfizer is looking for partners to make Covid drug in IndiaThe company has begun investing $1 billion, at risk, in the manufacture of its potential Covid-19 oral antiviral drug with the goal of maki...
- Pill 88% effective if given early, says PfizerFinal results of Paxlovid demonstrated reduction of hospitalisation or death by 89% among high-risk patients treated within three days of s...
- Pfizer says antiviral pill cut hospitalisation by 89%, neutralised Omicron in lab testsThe company said the 88% efficacy in patients treated within five days of symptom onset, was an increase from the 85% observed in the inter...
Load More
